CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK) has recently announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical holds on clinical trials of three of its CAR T-cell therapies in the United States. These therapies include zevorcabtagene autoleucel (zevor-cel, CT053), which targets BCMA, satricabtagene autoleucel (satri-cel, CT041), targeting Claudin18.2, and CT071, targeting GPRC5D.
CARsgen Therapeutics Holdings Limited is a biopharmaceutical company with operations in China and the U.S. that focuses on developing innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. The company has a comprehensive research and development platform covering target discovery, CAR T-cell development, clinical trials, and production. CARsgen is dedicated to addressing challenges faced by existing CAR T-cell therapies by improving safety, efficacy in treating solid tumors, and reducing treatment costs. The company’s mission is to become a global leader in biopharmaceuticals, providing innovative cell therapies for cancer patients worldwide.
The statements made in this press release are forward-looking, expressing the company’s views, projections, beliefs, and expectations for future events. These statements are based on assumptions and factors beyond the company’s control, subject to significant risks and uncertainties. Actual events or results may differ from the forward-looking statements, and the forward-looking events discussed may not occur. Risks and uncertainties detailed in the company’s annual and interim reports, as well as other announcements and reports on their corporate website, should be considered.
For more information, please visit the CARsgen Therapeutics Holdings Limited website at https://www.carsgen.com/.